Skip to content
Screener

AnaptysBio, Inc. ANAB Biopharma Company — General And Administrative Expense

Other segment segments

Royalty Management Company
$7.35M

Similar metrics at other companies

Contango Silver & Gold logo
CTGOJoint Venture Company — General And Administrative Expense
$0
Beam Therapeutics logo
BEAMExternal General And Administrative Expenses — General And Administrative Expense
$13.37M+149%
Solid Biosciences Inc. logo
SLDBExternal General And Administrative Expense — General And Administrative Expense
$6.33M+19.9%
Solid Biosciences Inc. logo
SLDBInternal General And Administrative Expense — General And Administrative Expense
$4.73M+40.9%
TRA
TRAXExternal Expenses — General And Administrative Expense
$8.72M+127%
Beam Therapeutics logo
BEAMEmployee Related Expenses — General And Administrative Expense
$11.95M+14.5%

Other financials

Income statement

See full
Revenue$25.6M-8.0%
Operating income-$34.6M-25.8%
Net income-$52.9M-34.5%
EPS (diluted)-$1.84-43.8%

Balance sheet

See full
Cash & equivalents$248.5M+152%
Total debt$13.6K-99.9%
Total equity$12.7M-62.5%
Total assets$329.7M-21.9%

Cash flow

See full
Operating cash flow-$25.9M-142%
CapEx$17.0K-51.4%
Free cash flow-$25.9M-142%

Valuation

See full
Market cap$1.62B+145%
Enterprise value$1.37B+117%
P/S+1.6×

Profitability

See full
Operating margin17.6%+9.6pp
Net margin-49.9%-22.6pp
FCF margin1.9%+1.0pp

Returns & leverage

See full
Return on equity-343.8%-1,012pp
Debt / equity-0.5×
Current ratio7.6×-0.7×

Where this comes from

Reported directly by AnaptysBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: AnaptysBio, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:20 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-219515
Line itemBiopharmaRoyalty ManagementTotal
Total R&D33,9553633,991
External G&A(3)8,7213,39812,119
Internal G&A(2)10,1353,94814,083
Total G&A18,8567,34626,202
Total operating expenses52,8117,38260,193
(Loss) income from operations(52,811)18,174(34,637)
Interest income2,3283252,653
Non-cash interest expense(20,859)(20,859)

Item 1. Consolidated Financial Statements

FAQ

What is AnaptysBio, Inc.'s biopharma company — general and administrative expense?
AnaptysBio, Inc. (ANAB) reported biopharma company — general and administrative expense of $18.86M in Q1 2026.
How has AnaptysBio, Inc.'s biopharma company — general and administrative expense changed year-over-year?
AnaptysBio, Inc.'s biopharma company — general and administrative expense increased by 92.1% year-over-year, from $9.82M to $18.86M.
What does biopharma company — general and administrative expense mean?
This metric captures the overhead costs required to support the company's operations, including executive compensation, legal, finance, and other corporate functions. It reflects the administrative burden of maintaining the business infrastructure outside of direct R&D activities. Investors monitor this to evaluate the company's operational discipline and cost management efficiency.

Ask your AI about AnaptysBio, Inc.'s biopharma company — general and administrative expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude